

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 October 2024 (03.10.2024)



(10) International Publication Number
WO 2024/206768 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) A61P 37/00 (2006.01)
A61P 35/00 (2006.01) A61P 37/08 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2024/022156

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:

29 March 2024 (29.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/493,453 31 March 2023 (31.03.2023) US

(71) Applicant: NOVAROCK BIOTHERAPEUTICS, LTD.

[US/US]; 801 Charles Ewing Blvd., Ewing, New Jersey
08628 (US).

(72) Inventors: HUANG, Haichun; 1728 Jockeys Way, Yard-
ley, Pennsylvania 19067 (US). LEI, Ming; 20 Lockwood
Drive, Princeton, New Jersey 08540 (US). PEI, Yi; 1836
Glenwold Drive, Paoli, Pennsylvania 19301 (US). LI, Han;
1 Claire Drive, Newtown, Pennsylvania 18940 (US). YU,
Yick Loi Raymond; 23 Windsor Drive, East Brunswick,
New Jersey 08816 (US). ZHU, Zhiqiang; 19 Galston Dri-
ve, West Windsor, New Jersey 08550 (US).

(74) Agent: BETTI, Christopher; 110 N Wacker Drive, Suite
2800, Chicago, Illinois 60606 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: ANTI-IL-25 ANTIBODIES AND METHODS OF USE THEREOF

(57) Abstract: The present disclosure provides antibodies and antibody fragments thereof that bind to IL-25. The disclosed antibodies and antibody fragments thereof can modulate a biological activity of the IL-25/IL-25 receptor signaling axis and are therefore useful for the treatment of Type 2 inflammation diseases, autoimmune diseases, allergic disorders or cancer.

WO 2024/206768 A1